The oral therapy Jascayd (nerandomilast) has been approved in Europe for adults with idiopathic pulmonary fibrosis and ...

Columnist Sam Kirton recounts his recent 17-day stay at Inova Fairfax Hospital after receiving a diagnosis of shingles.

Not being able to help with farm chores since her pulmonary fibrosis diagnosis has been a difficult adjustment for columnist ...

The Pulmonary Fibrosis Foundation added two experienced ILD specialists to its board as it advances a five-year strategic ...

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

Trevi Therapeutics plans to launch two pivotal Phase 3 clinical trials to continue testing Haduvio (nalbuphine extended-release) as a treatment for people with idiopathic pulmonary fibrosis (IPF) who ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary fibrosis (IPF) and chronic cough. That’s ...

Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their main goals, showing that the inhalation therapy significantly outperformed a ...